Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 37Terminated 6Unknown 5Withdrawn 2

Sponsor Class

NIH 4FED 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 4Breast 1

Conditions

Prostatic Neoplasms 4Breast Neoplasms 1

Interventions

Cisplatin 512Radiotherapy 376Cyclophosphamide 361Carboplatin 354Capecitabine 341Oxaliplatin 331Paclitaxel 328Gemcitabine 318Docetaxel 314Fluorouracil 288Drug Therapy 271apatinib 245Bevacizumab 243camrelizumab 217Etoposide 200Irinotecan 182Doxorubicin 180Leucovorin 160Dexamethasone 160pembrolizumab 150sintilimab 143Neoadjuvant Therapy 142anlotinib 139Pemetrexed 138Cytarabine 138Blood Specimen Collection 138Surgical Procedures, Operative 130toripalimab 128Radiosurgery 127S 1 (combination) 124

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Estramustine × Clear all
NCT00002775 2014-01-06

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
37 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003066 2014-01-06

Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
40 enrolled
Breast

Breast Neoplasms

NCT00003633 2013-12-19

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

National Cancer Institute (NCI)

Phase 1 Unknown
12 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003717 2013-12-19

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
17 enrolled
Genitourinary

Prostatic Neoplasms

NCT00218205 2005-09-22

A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer

Department of Veterans Affairs, New Jersey

Phase 2 Unknown
28 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡